# PQX-CLT-013 — Parallel PQX Trial Closure Artifact

- **Date:** 2026-03-28
- **Prompt type:** REVIEW
- **Parent protocol:** `docs/reviews/2026-03-27-parallel-pqx-trial-plan.md`

## Slices used

- **Slice A:** PQX-CLT-013 — Parallel PQX trial closure artifact (`docs/reviews/2026-03-27-parallel-pqx-trial-closure.md`)
- **Slice B:** Step 11 — Activate governance enforcement roadmap (`docs/governance/governance-enforcement-step-11-activation.md`, `docs/review-actions/2026-03-28-pqx-clt-012-parallel-trial-actions.md`)

## Merge order

- **Planned:** Slice A first, Slice B second.
- **Executed:** Slice A first (`c152f83`), Slice B second (`a7d7e1b`).

## Validation outcomes

- **Slice A validation:** PASS (`pytest -q tests/test_control_loop_certification.py`, `pytest -q tests/test_evaluation_enforcement_bridge.py`; scope diff only closure artifact).
- **Slice B validation:** PASS (`pytest -q tests/test_control_loop_certification.py`, `pytest -q tests/test_evaluation_enforcement_bridge.py`; scope diff only Step 11 governance docs).
- **Cross-diff isolation check:** PASS (no file overlap, no semantic overlap, no shared mutable assumptions).
- **Post-merge validation:** PASS (certification/promotional path checks unchanged and deterministic).

## Decision

- **Isolation held:** YES
- **Decision:** approved
- **Decision rationale:** Both slices were created from a shared baseline, implemented in isolated branch/file scopes, validated independently, merged in risk order without conflict, and revalidated post-merge with no certification/control-path regressions.
